Navigation Links
BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
Date:4/14/2009

WOBURN, Mass., April 14 /PRNewswire/ -- BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced today that its OPTiM (OncoVEX Pivotal Trial in Melanoma) Phase 3 study with OncoVEX (GM-CSF) in previously treated patients with Stage III and Stage IV melanoma had initiated. The study has commenced recruiting patients in the U.S. with sites in the United Kingdom, Germany and Australia due to open later in the year. Further details on this study can be found at www.oncovexgmcsf.com and at www.clinicaltrials.gov.

Dr Robert Coffin, Founder and Chief Technology Officer of BioVex Inc said:

"The treatment options for patients with recurrent or metastatic melanoma are currently very limited, with no therapy being approved or recognized to be effective in the second line setting and beyond. Currently, there are also very few late stage or pivotal clinical studies available for patients who have failed first line therapy. The initiation of this study, following the highly encouraging data generated in Phase 2, is therefore a significant milestone on the path towards meeting this major unmet need, and towards the approval of OncoVEX (GM-CSF) in this first indication."

OPTiM Phase 3 Trial Design

The OPTiM trial is a multi-national, open label, randomized Phase 3 study designed to assess the efficacy and safety of treatment with OncoVEX (GM-CSF) as compared to subcutaneously administered GM-CSF in patients with unresectable stage III (b-c) and Stage IV (M1a-c) disease. Patients will have received at least one prior therapy for active disease which includes any type of therapy including investigational drugs. A total of 360 patients will be enrolled (240 to
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioVex Raises $40 Million in First Close of Series F Financing
2. BioVex to Present at the UBS Global Life Sciences Conference
3. BioVex Closes Second Round of Series E Financing
4. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
5. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
6. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
7. BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00 Per Share
8. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
9. SenesTech, Inc. Commences Product Registration Process With Australian Government
10. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
11. Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Calif. , March 3, 2015 AtheroNova Inc. ... AtheroNova Operations, Inc., filed voluntary petitions under Chapter 11 of ... District of California , Santa ... 2015. The Company,s Chapter 11 cases are expected to be ... including a Bankruptcy Court supervised asset sale process, for all ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Becht ... today that it has acquired The CECON Group, ... the transaction were not announced. , Becht Engineering ... the energy sector including oil and gas production, ... fossil and nuclear power sectors. The company has ...
(Date:3/3/2015)... CAMBRIDGE, Mass. (PRWEB) March 03, 2015 ... driven by Semantic Web technology, today announced that it ... ‘100 Companies That Matter in Knowledge Management.’ , ... select group of colleagues, analysts and system integrators who ... and delivery of the right information to the right ...
(Date:3/3/2015)... Mar. 03, 2015 Research and Markets ... PharmaBiotech,s new report "RNAi - Technologies, Markets and ... Because of its ability to silence any gene once ... the research tool to discriminate gene function. After the ... designed to target every gene in the genome and ...
Breaking Biology Technology:AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 4Cambridge Semantics Named to KMWorld’s 2015 ‘100 Companies That Matter in Knowledge Management’ 2Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 2Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 3
... ... ... ... ...
... ... to bring more attention to the need for finding more treatments for diseases which affect ... ... to the urgent need of finding more treatments for rare diseases by partnering with the ...
... ... ... , , ... IGEN Networks Corp. (IGEN: OTCBB) , ...
Cached Biology Technology:Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 2Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 3Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 4Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 5Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 6Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 7Raising Awareness of Rare Diseases, Anson Group Announces Sponsorship of Rare Disease Day 2IGEN Networks appoints directors and provides business update 2IGEN Networks appoints directors and provides business update 3
(Date:2/12/2015)... , Feb. 12, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62/113114 for DISTRIBUTED METHOD AND ... The patent further establishes NXT-ID,s position in the ... property portfolio the ability for multiple devices to collaborate ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America recently ... for carbon nanotube (CNT) macrostructures, including sheets, yarns and ... (UTD). Leveraging the vast industrial resources of ... Japan , Lintec of America is forming the ... TX , focusing on scaling up the manufacturing ...
(Date:2/5/2015)... Epic Sciences , a precision diagnostics company dedicated to improving ... , Ph.D., president and CEO, is scheduled to present at ... Valley, which is taking place at the Computer History Museum ... 26-28, 2015. Dr. Prahalad will give a ... Epic Sciences was a finalist in the PMWC,s Most Promising ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... , LAS VEGAS , April 27 In its third ... open to a more inclusive pool of contestants and takes place three times ... Championship) invites any company with tea inventory in North America to ... harvests of hot tea, as well as iced tea. , ...
... April 27 From international jetsetter to model to entrepreneur, ... resume as she unveils her debut collection for QVC. The Slovenian beauty is scheduled ... PM (ET) to debut the Melania™ Timepieces & Fashion Jewelry line ... , , ...
... with a volume equivalent to 40 Amazon Rivers has been ... in the Indian Ocean sector of the Southern Ocean, 4200 ... Nature Geoscience , the researchers described the current more ... important pathway in a global network of ocean currents that ...
Cached Biology News:World Tea Expo Throws Open Door to Tea Championship 2Melania Trump Takes 'Time' To Shine With New QVC(R) Collection 2Melania Trump Takes 'Time' To Shine With New QVC(R) Collection 3Melania Trump Takes 'Time' To Shine With New QVC(R) Collection 4Massive Southern Ocean current discovered 2
... System - dUTP with CyScribe GFX ... generation and purification of Cy3- and ... for complete cDNA labeling and purification.Flexible ... for performing labeling reactions with either ...
Collected from sexually mature, mixed sex, mixed breed dogs. Serum from specific breeds available by request....
Homo sapiens toll interacting protein Antigen: Recombinant Protein...
... 1. 1000 V, 400 mA, 100 ... constant power modes.Single-unit increments in settings ... and recalls three protocols.Outstanding choice for ... Multiphor II or GenePhor systems. Category: ...
Biology Products: